BOSTON & DAEJEON, South Korea--(BUSINESS WIRE)--Orum Therapeutics, Inc. (“Orum”), a private biotechnology company pioneering the development of tumor-directed targeted protein degraders (TPDs), today announced that it will present new preclinical data for its ORM-5029, ORM-6151, and PD-1-Cbl-b programs in three separate presentations at the American Association for Cancer Research (AACR) Annual Meeting 2023 taking place April 14-19 in Orlando.
ORM-5029 is a potential first-in-class targeted protein degrader therapy currently in a Phase 1 clinical trial for HER2-expressing breast cancer. ORM-6151 is currently in the IND-enabling stage for CD33-positive hematologic malignancies, such as acute myeloid leukemia (AML). Orum’s PD-1-Cbl-b immuno-oncology program utilizes a novel approach designed to deliver proprietary Cbl-b inhibitors specifically to PD-1-expressing exhausted T cells, while blocking PD-1/PD-L1 interaction. This strategy is expected to limit systemic exposure of Cbl-b inhibitors and minimize c-Cbl inhibition that can lead to off-target toxicity.
Poster Title: Development of RNAscope multiplex-based assay for exploratory pharmacodynamic biomarkers assessment in breast cancer patients from Phase I clinical trial of ORM-5029, a potent GSPT1 degrader
Date and Time: Monday April 17, 9:00 AM - 12:30 PM ET
Session Category: Clinical Research Excluding Trials
Session Title: Biomarkers for Elucidation of Tumor Biology and Metastasis
Session Location: Section 38
Poster Board Number: 21
Abstract number: 2118
Poster Title: ORM-6151: A first-in-class CD33-antibody enabled GSPT1 degrader for AML
Date and Time: Monday, April 17, 1:30PM - 5:00PM ET
Session Category: Experimental and Molecular Therapeutics
Session Title: Drug Delivery Systems
Session Location: Section 15
Poster Board Number: 3
Abstract number: 2700
Poster Title: A novel antibody-enabled dual precision targeted protein stabilization (TPS²) that augments anti-tumor immune response by targeting CBL-B inhibitor to exhausted T cells while blocking checkpoint molecule, PD-1
Date and Time: Tuesday Apr 18, 9:00 AM - 12:30 PM ET
Session Category: Clinical Research Excluding Trials
Session Title: Immunomodulatory Agents and Interventions
Session Location: Section 40
Poster Board Number: 22
Abstract number: 4436
About Orum’s GSPT1 Platform Using the TPD² ™ Approach
Orum’s GSPT1 platform uses the company’s unique Dual-Precision Targeted Protein Degradation (TPD²) approach to build novel targeted protein degraders combined with the precise tumor cell delivery mechanisms of antibodies to generate innovative, first-in-class, cell-specific TPDs for the treatment of cancer. Orum has developed new molecular glue degrader payloads to specifically degrade an intracellular target protein within cancer cells via the E3 ubiquitin ligase pathway. Conjugated to antibodies, the payloads are designed to be delivered specifically to cancer cells and degrade the intracellular target protein GSPT1 and cause tumor cell death.
About Orum’s TPS² ™ Approach
Orum’s Dual-precision Targeted Protein Stabilization (TPS²) approach combines novel targeted protein inhibitors with the precise cell delivery mechanism of antibodies to increase the levels of intracellular target proteins in a cell-type-specific manner for oncology and immuno-oncology. The first program applying the TPS² approach is a Cbl-b inhibitor (Cbl-bi) conjugated to anti-PD-1 antibody. By delivering Cbl-bi specifically to exhausted T cells, the conjugate restores effector T cell function where PD-1 checkpoint blockade alone is insufficient, while also enabling T cells to overcome the immunosuppressive mechanisms in a tumor microenvironment.
About Orum Therapeutics
Orum Therapeutics is a private, clinical-stage biotech pioneering the development of tumor-directed targeted protein degraders by leveraging its TPD² approach to provide antibody-enabled cell-specific delivery. The company’s proprietary platforms generated using the TPD² approach include the GSPT1 platform, which generates first-in-class antibody drug conjugates. The first therapeutic candidates from the GSPT1 platform are in development for the treatment of solid tumors and hematologic cancers. Orum is located in Boston, US, and Daejeon, South Korea. For more information, visit www.orumrx.com.
This press release contains forward-looking statements that are based on the current expectations and beliefs of Orum. Statements in this release regarding matters that are not historical facts, including, but not limited to, statements relating to the successful development and clinical benefits of novel targeted protein degraders and Cbl-b inhibitor immuno-oncology products, the potential for translation of preclinical data to positive clinical results, the potential for filing of Investigational New Drug applications, the commencement and successful completion of clinical trials, the potential for development of other product candidates, and the preferability of Orum’s products to others available are forward looking statements. These forward-looking statements are based on management’s expectations and assumptions as of the date of this release and are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, without limitation, the uncertain and continually changing impacts and expected duration of any global pandemic; the uncertainty of success in research and development activities; risks related to clinical trials, including potential delays, safety issues, or negative results; competition from alternative therapies; the risk that Orum may not be able to maintain and enforce its intellectual property; the risk that product candidates may not be successfully commercialized or adopted; the availability of financing; and risks related to the recruitment and retention of key employees, fluctuating markets and economic conditions, health care reform, prices, and reimbursement rates. The forward-looking statements in this presentation speak only as of the date of this release, and Orum undertakes no obligation to update or revise any of the statements. Orum cautions investors not to place considerable reliance on the forward-looking statements contained in this release.